RE: RE: French Upstart Rebuffs Veteran DrugmakersI think the Cerenis article is a little optimistic in its clinical trial information. The trial details were updated by Cerenis at www.clinicaltrials.gov at the end of March so they're very current. They've just started recruiting.
Cerenis is due to stop dosing in April of 2012 with trial results to be released in October of 2012. But their eligibility criteria are very similar to the difficult ones developed and abandoned by RVX for the ASSURE trial. Since treatment of each patient takes only two months then the trial end date could shift all over the place.
What would be great would be an early termination of the trial and a release of excellent data (à l'Esperion). With the short treatment period and with potentially significant plaque regression in the early patients, it may be obviously unacceptable to put the entire 504 patients through the invasive IVUS procedures, especially with patients being quite sick to begin with. If the trial is stopped for good reasons then we would probably see a big anticipatory gap upward in RVX share price, especially since RVX and Cerenis are not really competitors.
Obviously, if RVX gaps up on some other company's news then those without RVX shares will be very disappointed.
You can find the Cerenis trial information right here.